NEW YORK, Dec. 30, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Innocoll Holdings, plc ("Innocoll" or the "Company") (NASDAQ: INNL). Such investors can obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/innl.
The investigation concerns whether Innocoll and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On December 29, 2016, Innocoll revealed that it had received a Refusal to File letter from the U.S. Food & Drug Administration ("FDA") regarding its New Drug Application for XARACOLL, a postsurgical pain treatment and the Company's lead product candidate. Innocoll said that the FDA stated that XARACOLL should have been categorized as a drug/device combination which would necessitate additional information. Following this news, Innocoll stock has dropped as much as $1.18 per share, or 66.7%, during intraday trading on December 30, 2016.
If you are aware of any facts relating to this investigation, or purchased Innocoll shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/innl. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article